ArticleEClinicalMedicine2024

Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial.

Yuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.